hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06369233, orgStudyIdInfo id: LNC-MS-002, briefTitle: Clinical Study to Evaluate the Anti-adhesion Efficacy and Safety of MegaShield®-SP in Comparison With Guardix-SP Plus After Spine Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-01, primaryCompletionDateStruct date: 2025-02-28, completionDateStruct date: 2025-02-28, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-25, sponsorCollaboratorsModule leadSponsor name: L&C Bio, class: INDUSTRY, collaborators name: PROMeDis, descriptionModule briefSummary: This study is Interventional, Parallel, Double-blinded, Randomized study. Subjects aged 20 to 70 years who had a Lumbar discectomy or laminectomy, MegaShield-SP® and Guardix-SP Plus will be applied., conditionsModule conditions: Herniation, Disc, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 80, type: ESTIMATED, armsInterventionsModule interventions name: MegaShield®-SP, interventions name: Guardix-SP Plus, outcomesModule primaryOutcomes measure: MRI scar score, secondaryOutcomes measure: Oswestry Disability Index(ODI) score, secondaryOutcomes measure: Visual Analog Scale(VAS) Back & Leg Pain Score, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Eunpyeong ST. Mary's Hospital, status: RECRUITING, city: Seoul, zip: 03312, country: Korea, Republic of, contacts name: HyungYul Park, role: CONTACT, phone: 02-2030-4536, email: matrixbest@naver.com, contacts name: HyungYul Kim, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.566, lon: 126.9784, locations facility: Severance Hospital, status: RECRUITING, city: Seoul, zip: 03722, country: Korea, Republic of, contacts name: Siyoung Park, role: CONTACT, phone: 2228-2194, email: drspine90@yuhs.ac, contacts name: Siyoung Park, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.566, lon: 126.9784, locations facility: Gangnam Severance Hospital, status: RECRUITING, city: Seoul, zip: 06273, country: Korea, Republic of, contacts name: Jiwon Kwon, role: CONTACT, phone: 2019-3411, email: KWONJJANNG@yuhs.ac, contacts name: Jiwon Kwon, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.566, lon: 126.9784, locations facility: Bundang Seoul National University Hospital, status: RECRUITING, city: Seoul, zip: 13620, country: Korea, Republic of, contacts name: Hojung Kim, role: CONTACT, phone: 031-787-7202, email: oshjkim@gmail.com, contacts name: Hojung Kim, Professor, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 37.566, lon: 126.9784, hasResults: False
protocolSection identificationModule nctId: NCT06369220, orgStudyIdInfo id: LIA-STI-542, briefTitle: A Study of the Cobas® Liat CT/NG/MG Test Versus Current Standard Practice for Managing Participants at Increased Risk of Sexually Transmitted Infections, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-15, primaryCompletionDateStruct date: 2024-10-31, completionDateStruct date: 2024-10-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Hoffmann-La Roche, class: INDUSTRY, collaborators name: Roche Molecular Systems, Inc, descriptionModule briefSummary: This study is designed to assess the comparative clinical utility of the point of care cobas® liat CT/NG/MG to current standard practices in the diagnosis and treatment of urogenital infections with Chlamydia trachomatis (CT), Neisseria gonorrhoeae (NG), and Mycoplasma genitalium (MG)., conditionsModule conditions: Chlamydia Trachomatis Infection, conditions: Neisseria Gonorrhoeae Infection, conditions: Mycoplasma Genitalium Infection, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: DIAGNOSTIC, maskingInfo masking: NONE, enrollmentInfo count: 348, type: ESTIMATED, armsInterventionsModule interventions name: cobas® liat CT/NG/MG nucleic acid test, interventions name: Standard of Care (SOC): Clinician's Standard Practice, outcomesModule primaryOutcomes measure: Percentage of Participants Given Inappropriate Treatments for All Pathogens Combined (CT, NG, and MG), secondaryOutcomes measure: Percentage of Participants Given Inappropriate Treatment for CT Infection, secondaryOutcomes measure: Percentage of Participants Given Inappropriate Treatment for NG Infection, secondaryOutcomes measure: Percentage of Participants Given Inappropriate Treatment for MG Infection, secondaryOutcomes measure: Mean Satisfaction and Confidence Rating Scores of SOC and POC, According to Healthcare Professionals' Responses to the CSDT Questionnaire, secondaryOutcomes measure: Mean Satisfaction Rating Scores of SOC and POC, According to Participants' Responses to the PSDT Questionnaire, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06369207, orgStudyIdInfo id: 113454, briefTitle: Investigation of the Transmission Pathways of Reflux in Patients With Chronic Venous Evaluation of Reflux Transmission Pathways in Chronic Venous Insufficiency Patients Secondary to Saphenofemoral Reflux, statusModule overallStatus: ACTIVE_NOT_RECRUITING, startDateStruct date: 2023-09-12, primaryCompletionDateStruct date: 2024-02-15, completionDateStruct date: 2024-09, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-22, sponsorCollaboratorsModule leadSponsor name: Golestan University of Medical sciences, class: OTHER, descriptionModule briefSummary: Chronic venous insufficiency (CVI) is one of the most common medical problems in adults that occurs secondary to the reflux of blood through incompetent valves of lower extremity veins. The most common involved valve is the valve located at the saphenofemoral junction. Although the pathway of reflux transmission is not the same in all patients, the removal or ablation of the greater saphenous vein (GSV) is considered a standard treatment in these patients. However, in patients whose reflux is transmitted to branches other than GSV, this treatment leads to the unnecessary destruction of a competent segment of GSV in addition to remaining at least some segments of incompetent veins. So, in this study, the investigators intend to investigate the different pathways of reflux transmission in chronic venous insufficiency patients who are candidates for GSV ablation/stripping because of saphenofemoral junction insufficiency. This cross-sectional study will be conducted with a descriptive-analytical approach. ., conditionsModule conditions: Venous Insufficiency, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ACTUAL, outcomesModule primaryOutcomes measure: Determination of reflux transmission pathways in CVI patients with SFJ incompetency, secondaryOutcomes measure: Anatomic variations of GSV in CVI patients with SFJ incompetency, secondaryOutcomes measure: Prevalence of reflux along GSV main trunk in CVI patients with SFJ incompetency, secondaryOutcomes measure: Prevalence of reflux along accessory saphenous veins in CVI patients with SFJ incompetency, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Pezhman Kharazm, MD, city: Gorgan, state: Golestan, zip: 4917956808, country: Iran, Islamic Republic of, geoPoint lat: 36.8427, lon: 54.44391, hasResults: False
protocolSection identificationModule nctId: NCT06369181, orgStudyIdInfo id: NET 2020, briefTitle: Neuroendocrine Transformation in RB1/TP53 Inactivated NSCLC, statusModule overallStatus: RECRUITING, startDateStruct date: 2021-01-01, primaryCompletionDateStruct date: 2027-12-31, completionDateStruct date: 2028-12-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: Histology transformation from non-small cell lung cancer (NSCLC) to neuroendocrine carcinomas (NEC), especially from epidermal growth factor receptor (EGFR) mutant lung adenocarcinoma (LADC) to small cell lung cancer (SCLC), is widely recognized as a rare mechanism for NSCLC to confer tyrosine kinase inhibitors (TKIs) resistance. The probability of its occurrence is about 3-14% in NSCLC patients who are resistant to TKI treatment. In addition to EGFR mutations, NSCLC patients carrying ALK/ROS1 mutations and receiving corresponding TKI treatment may also experience NEC transformation(NET).In a previous study \[Pubmed ID: 35609408\], the investigators demonstrated that NET also develops in NSCLCs without TKI targets or treatments. This phenomenon could be under-recognized, because re-biopsy was less frequently performed in these patients. The investigators had also shown that p53/Rb inactivation might correlated with NET and should be considered for NET risk prediction. In another retrospective studies, it was found that NSCLC patients with RB1/TP53 dual inactivation mutations had a significantly higher probability of NEC pathological transformation than those without RB1/TP53 inactivation mutations (43 times higher than those without mutations). Therefore, the subgroup of NSCLC patients with tumor suppressor gene RB1/TP53 dual inactivation might have elevated risk for NET.In this study, the investigators proposed to prospectively follow up NSCLC patients with dual RB1/TP53 inactivation (approximately 5% of the total NSCLC). Through prospective and systematic collection of baseline pathological information, clinical treatment process, and imaging data, and as much as possible, repeat pathological biopsies will be performed during disease progression., conditionsModule conditions: Neuroendocrine Carcinoma, conditions: Non-small Cell Lung Cancer, conditions: Histology Transformation, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 50, type: ESTIMATED, outcomesModule primaryOutcomes measure: neuroendocrine transformation rate, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Zhengfei Zhu, MD, role: CONTACT, phone: +86 18017312901, email: fuscczzf@163.com, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06369168, orgStudyIdInfo id: Kliniken Essen-Mitte, briefTitle: Auricular Acupuncture and Hot Flashes During Adjuvant Endocrine Therapy, acronym: OhrHit, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-05-20, primaryCompletionDateStruct date: 2024-11-20, completionDateStruct date: 2025-11-20, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-23, sponsorCollaboratorsModule leadSponsor name: Kliniken Essen-Mitte, class: OTHER, collaborators name: Karl and Veronica Carstens Foundation, descriptionModule briefSummary: With this clinical trial we investigate whether auricular acupuncture during adjuvant endocrine therapy has an improving effect on hot flashes, which are often perceived as psychologically and physically stressful in self-assessment of women with breast cancer.Empirical studies indicate that body acupuncture has positive effects on hot flashes. As auricular acupuncture offers a number of advantages over body acupuncture, a three-armed randomised controlled research design is being used to investigate whether hot flashes caused by endocrine therapy are also reduced by ear acupuncture. Balanced ear acupuncture will be compared with NADA ear acupuncture in terms of efficacy and effectiveness. In addition, the effects of the two forms of therapy on the patients' individual quality of life, fatigue, stress perception and sleep quality will be analysed., conditionsModule conditions: Hot Flashes, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: randomized controlled trial, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: PARTICIPANT, enrollmentInfo count: 99, type: ESTIMATED, armsInterventionsModule interventions name: auricular acupuncture, outcomesModule primaryOutcomes measure: subscale somato-vegetative symptoms of the Menopause Rating Scale (MRS), secondaryOutcomes measure: Menopause Rating Scale (MRS) total score, secondaryOutcomes measure: Psychological symptoms and urogenital symptoms subscales of the MRS, secondaryOutcomes measure: functional assessment of cancer therapy - breast (FACT-B), secondaryOutcomes measure: perceived stress questionnaire (PSQ), secondaryOutcomes measure: insomnia severity index (ISI), secondaryOutcomes measure: big five inventory (BFI), secondaryOutcomes measure: Expected effect of the respective intervention on a 100mm visual analogue scale, secondaryOutcomes measure: intensity and degree of impairment due to hot flashes on a 100mm visual analogue scale, secondaryOutcomes measure: adverse events (AEs), eligibilityModule sex: FEMALE, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False
protocolSection identificationModule nctId: NCT06369155, orgStudyIdInfo id: 24-061, briefTitle: Azenosertib in Uterine Serous Carcinoma: Biomarker Study, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-09, primaryCompletionDateStruct date: 2026-01-31, completionDateStruct date: 2027-01-31, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Joyce Liu, MD, class: OTHER, collaborators name: National Cancer Institute (NCI), collaborators name: Zentalis, descriptionModule briefSummary: This research study is being done to investigate how Azenosertib affects tumor cells of persistent or recurrent uterine serous carcinoma.The name of the study drug involved in this study is:-Azenosertib (a type of Wee1 inhibitor), conditionsModule conditions: Uterine Serous Carcinoma, conditions: Uterine Carcinoma, conditions: Uterine Cancer, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: NA, interventionModel: SINGLE_GROUP, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 25, type: ESTIMATED, armsInterventionsModule interventions name: Azenosertib, outcomesModule primaryOutcomes measure: Percentage Change in Replication Fork Speed in Overall Response, primaryOutcomes measure: Percentage Change in Replication Fork Speed in 6 Month Progression Free Survival (PFS6), secondaryOutcomes measure: Overall Response Rate (ORR), secondaryOutcomes measure: 6-month Progression-Free Survival (PFS6), secondaryOutcomes measure: Clinical Benefit Rate (CBR), secondaryOutcomes measure: Median Duration of Overall Response (DOR), secondaryOutcomes measure: Median Progression-Free Survival (PFS), secondaryOutcomes measure: Grade 3-5 Treatment-related Toxicity Rate, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Brigham and Women's Hospital, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Joyce Liu, MD, MPH, role: CONTACT, phone: 617-632-5269, email: joyce_liu@dfci.harvard.edu, contacts name: Joyce Liu, MD, MPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, locations facility: Dana-Farber Cancer Institute, city: Boston, state: Massachusetts, zip: 02215, country: United States, contacts name: Joyce Liu, MD, MPH, role: CONTACT, phone: 617-632-5269, email: joyce_liu@dfci.harvard.edu, contacts name: Joyce Liu, MD, MPH, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 42.35843, lon: -71.05977, hasResults: False
protocolSection identificationModule nctId: NCT06369129, orgStudyIdInfo id: CEBD-CU-2024-06-16, briefTitle: Accuracy& Orbital Volume Using Patient Specific Titanium Implant Vs Zirconia for Orbital Floor Reconstruction, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-06, primaryCompletionDateStruct date: 2025-08, completionDateStruct date: 2025-08, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-17, sponsorCollaboratorsModule leadSponsor name: Cairo University, class: OTHER, descriptionModule briefSummary: Comparative study used to assess if the patient specific zirconia implant will provide better accuracy, intraoperative adaptability, precise orbital volume and soft tissue reaction with more cost effectiveness than the patient specific titanium implants in orbital floor reconstruction after blow out fractures ., conditionsModule conditions: Blow-Out Fractures, conditions: Orbital Fractures, conditions: Orbital Floor Fracture, conditions: Orbital Trauma, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: A randomized clinical trial.* Parallel group study.* A trial will be carried out in hospital of Oral and Maxillofacial surgery department - Faculty of Oral and Dental Medicine - Cairo University .* Equal randomization : participants with equal probabilities for intervention.* Positive controlled : Both groups receiving treatment., primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 20, type: ESTIMATED, armsInterventionsModule interventions name: Orbital floor reconstruction with Patient Specific Zirconia Implant, interventions name: Orbital floor reconstruction with Patient Specific Titanium Implant, outcomesModule primaryOutcomes measure: Orbital Volume, secondaryOutcomes measure: Accuracy of the patient specific implant in the orbital floor reconstruction, secondaryOutcomes measure: Cost effectiveness, secondaryOutcomes measure: Patient satisfaction, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 60 Years, stdAges: ADULT, contactsLocationsModule locations facility: Cairo University, status: RECRUITING, city: Cairo, zip: 11511, country: Egypt, contacts name: OLA A. ELMORSY, PHD, role: CONTACT, phone: 00201141234877, email: dr.ola.elmorsy@gmail.com, geoPoint lat: 30.06263, lon: 31.24967, hasResults: False
protocolSection identificationModule nctId: NCT06369116, orgStudyIdInfo id: CLS-017B, secondaryIdInfos id: HSTAR012, type: OTHER, domain: HSTAR Programme, secondaryIdInfos id: WRHI071, type: OTHER, domain: Ezintsha, briefTitle: Trial of Hepatitis C Self-Testing in the Hands of Untrained Lay Users, statusModule overallStatus: RECRUITING, startDateStruct date: 2023-10-12, primaryCompletionDateStruct date: 2023-11-17, completionDateStruct date: 2024-04-22, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: bioLytical Laboratories, class: INDUSTRY, descriptionModule briefSummary: This is a controlled study intended to evaluate the usability, label comprehension and performance of the INSTI® HCV Self Test in the hands of untrained lay users using fingerstick blood, with instructions for use specifically designed for a lay person who has not used any hepatitis C rapid self test prior to the study and to assess "lay" users ability to comprehend key concepts and information provided on the outside of the pouch and in the accompanying Instructions for Use. Comprehension will be assessed without product familiarization (demonstration/training) by a healthcare professional., conditionsModule conditions: Hepatitis C, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: SINGLE_GROUP, interventionModelDescription: Participants are recruited and enrolled to conduct INSTI HCV Self Test and then participate in the usability portion of the study., primaryPurpose: SCREENING, maskingInfo masking: SINGLE, whoMasked: CARE_PROVIDER, enrollmentInfo count: 1400, type: ESTIMATED, armsInterventionsModule interventions name: INSTI HCV Self Test, outcomesModule primaryOutcomes measure: Clinical sensitivity and specificity of INSTI HCV Self Test, secondaryOutcomes measure: To assess the usability and label comprehension of the INSTI HCV Self Test, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Ezintsha, a division of Wits Health Consortium (Pty) Ltd, status: RECRUITING, city: Parktown, zip: 2193, country: South Africa, contacts name: Vanessa Tiyamike Msolomba, role: CONTACT, phone: +27 74 830 9063, email: vmsolomba@ezintsha.org, geoPoint lat: -26.18205, lon: 28.02671, hasResults: False
protocolSection identificationModule nctId: NCT06369103, orgStudyIdInfo id: FMBSUREC/03032024/Fakhry, briefTitle: The Sedative Effects of Dexmedetomidine VS Propofol During Peribulbar Anesthesia in Patients Undergoing Vitrectomy Surgery, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-05-01, primaryCompletionDateStruct date: 2025-05-01, completionDateStruct date: 2025-05-01, studyFirstPostDateStruct date: 2024-04-16, lastUpdatePostDateStruct date: 2024-04-16, sponsorCollaboratorsModule leadSponsor name: Beni-Suef University, class: OTHER, descriptionModule briefSummary: The aim of the work to compare the Sedative Effects of Dexmedetomidine and Propofol during peribulbar anesthesia in patients undergoing vitrectomy surgery on hemodynamic, respiratory parameters, recovery profile, analgesic effects, post-operative cognitive function, patients satisfaction and adverse events., conditionsModule conditions: Patient, conditions: Satisfaction, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: NONE, enrollmentInfo count: 420, type: ESTIMATED, armsInterventionsModule interventions name: Dexmedetomidine, interventions name: Propofol, outcomesModule primaryOutcomes measure: Patient satisfaction, secondaryOutcomes measure: Visual analogue scale, eligibilityModule sex: ALL, minimumAge: 20 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beni Suef University Hospital, status: RECRUITING, city: Banī Suwayf, state: Beni Suef, zip: 62814, country: Egypt, contacts name: Dina M Fakhry, MD, role: CONTACT, phone: 0201289998680, email: dina_fakhry_91@yahoo.com, contacts name: Dina M Fakhry, MD, role: CONTACT, phone: +201289998680, email: dina_fakhry_91@yahoo.com, geoPoint lat: 29.07441, lon: 31.09785, hasResults: False